Compare RDY & FROG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDY | FROG |
|---|---|---|
| Founded | 1984 | 2008 |
| Country | India | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9B | 10.5B |
| IPO Year | 2001 | 2020 |
| Metric | RDY | FROG |
|---|---|---|
| Price | $12.18 | $92.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 20 |
| Target Price | $16.90 | ★ $65.75 |
| AVG Volume (30 Days) | ★ 2.3M | 2.2M |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.52% | N/A |
| EPS Growth | N/A | ★ 1.59 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $531,840,000.00 |
| Revenue This Year | $7.72 | $20.37 |
| Revenue Next Year | $3.50 | $16.99 |
| P/E Ratio | $18.67 | ★ N/A |
| Revenue Growth | N/A | ★ 24.12 |
| 52 Week Low | $11.36 | $34.05 |
| 52 Week High | $15.67 | $105.76 |
| Indicator | RDY | FROG |
|---|---|---|
| Relative Strength Index (RSI) | 44.65 | 50.87 |
| Support Level | $11.99 | $86.04 |
| Resistance Level | $12.38 | $98.85 |
| Average True Range (ATR) | 0.16 | 5.80 |
| MACD | 0.03 | 0.38 |
| Stochastic Oscillator | 32.69 | 28.50 |
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
JFrog Ltd provides an end-to-end, hybrid, universal DevOps Platform that powers and controls the software supply chain, enabling organizations to continuously and securely deliver software updates across any system. Its product portfolio includes JFrog Artifactory; JFrog Pipelines; JFrog Xray; JFrog Distribution; JFrog Artifactory Edge; JFrog Mission Control and JFrog Insight. Geographically, it derives a majority of revenue from united states and also has its presence in Israel, India and other regions.